Optimal timing of antiretroviral therapy initiation in patients coinfected with HIV and tuberculosis

References

• Singh A, Bairy I, Shivananda PG. Spectrum of opportunistic infections in AIDS cases. Indian J. Med. Sci.57(1), 16–21 (2003).
   PubMedGoogle Scholar
• Putong NM, Pitisuttithum P, Supanaranond W et al. Mycobacterium tuberculosis infection among HIV/AIDS patients in Thailand: clinical manifestations and outcomes. Southeast Asian J. Trop. Med. Public Health33(2), 346–351 (2002).
   PubMedGoogle Scholar
• Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J, de Cock KM. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.4(8), 705–712 (2000).
   PubMed Web of Science ®Google Scholar
• Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS15(2), 143–152 (2001).
   PubMed Web of Science ®Google Scholar
• Centers of Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb. Mortal. Wkly Rep.47(RR-20), 1–58 (1998).
   PubMedGoogle Scholar
• Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin. Infect. Dis.50(S3), S223–S230 (2010).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am. J. Respir. Crit. Care. Med.167(4), 603–662 (2003).
   PubMed Web of Science ®Google Scholar
• Jongwutiwes U, Sungkanuparph S, Kiertiburanakul S. Comparison of clinical features and survival between cryptococcosis in human immunodeficiency virus (HIV)-positive and HIV-negative patients. Jpn J. Infect. Dis.61(2), 111–115 (2008).
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J. Acquir. Immune Defic. Syndr.43(1), 42–46 (2006).
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med.338(13), 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL; National Center for Infectious Diseases, Division of HIV/AIDS. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm. Rep.41(RR-17), 1–19 (1992).
   Google Scholar
• Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr. Opin. HIV AIDS5(1), 61–69 (2010).
   PubMed Web of Science ®Google Scholar
• Nahid P, Gonzalez LC, Rudoy I et al. Treatment outcomes of patients with HIV and tuberculosis. Am. J. Respir. Crit. Care Med.175(11), 1199–1206 (2007).
   PubMed Web of Science ®Google Scholar
• Kiertiburanakul S. Immune reconstitution inflammatory syndrome in HIV-infected patients with tuberculosis. J. Med. Assoc. Thai.93(2), 257–264 (2010).
   PubMedGoogle Scholar
• Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving anti-TB and antiretroviral therapy. J. Infect.53(6), 357–363 (2006).
   PubMed Web of Science ®Google Scholar
• McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J. Infect. Dis.196(Suppl. 1), S63–S75 (2007).
   PubMed Web of Science ®Google Scholar
• Dean GL, Edwards SG, Ives NJ et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS16(1), 75–83 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson D, Meintjes G. Timing of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med.362(22), 2137 (2010).
   PubMedGoogle Scholar
• Abdool Karim SS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med.362(8), 697–706 (2010).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect. Dis.5(6), 361–373 (2005).
   PubMed Web of Science ®Google Scholar
• Pedral-Sampaio DB, Alves CR, Netto EM, Brites C, Oliveira AS, Badaro R. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz. J. Infect. Dis.8(3), 211–216 (2004).
   PubMedGoogle Scholar
• Breen RA, Smith CJ, Bettinson H et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax59(8), 704–707 (2004).
   PubMed Web of Science ®Google Scholar
• Breton G, Duval X, Estellat C et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin. Infect. Dis.39(11), 1709–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir. Ther.10(3), 417–422 (2005).
   PubMed Web of Science ®Google Scholar
• Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M; IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis.10(4), 251–261 (2010).
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Techasathit W, Utaipiboon C et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed.4(4), 515–528 (2010).
   Web of Science ®Google Scholar
• Shao HJ, Crump JA, Ramadhani HO et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res. Hum. Retroviruses25(12), 1277–1285 (2009).
   PubMed Web of Science ®Google Scholar
• Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J. Infect. Dis.196(Suppl. 1), S46–S51 (2007).
   PubMed Web of Science ®Google Scholar
• Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am. J. Resp. Crit. Care Med.159(3), 733–740 (1999).
   PubMed Web of Science ®Google Scholar
• Breen RA, Swaden L, Ballinger J, Lipman MC. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs66(18), 2299–2308 (2006).
   PubMed Web of Science ®Google Scholar
• Habib AG. A clinical and epidemiologic update on the interaction between tuberculosis and human immunodeficiency virus infection in adults. Ann. Afr. Med.8(3), 147–155 (2009).
   PubMedGoogle Scholar